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Abbreviations 
 
AlF3 Aluminum Fluoride 
AVP Arginine VasoPressin 
β2AR β2 Adrenergic Receptor 
C5aR  C5a Chemotactic Receptor 
DAG DiAcylGlycerol 
DOR  δ opiod receptor 
DPDPE  [D-Pen2,5]-enkephalin 
CAM  Constitutively Active Mutant 
EDG-6 Endothelial Differentiation, G-protein-coupled 6 
ER Endoplasmic Reticulum 
FAK Focal Adhesion Kinase 
FPR Formyl Peptide Receptors 
GAP GTPase Activating Proteins 
GEF Guanine nucleotide Exchange Factor 
GDI Guanine nucleotide Dissociation Inhibitor  
GPCR  G Protein Coupled Receptor 
GRK G protein-coupled Receptor Kinase 
HCMV Human CytoMegaloVirus 
IP3 Inositol (1,4,5)-trisPhosphate 
Iso Isoproterenol 
MAPK Mitogen Activated Protein Kinase 
PKC Protein Kinase C 
PHA PhytoHaemAgglutinin 
PIP2 PhosphatidylInositol (4,5)-bisPhosphate 
PLC PhosphoLipase C 
RGS Regulator of G protein Signalling 
SDF-1 Stromal Derives factor 1 
SOCE Store-Operated Ca2+ Entry 
STAT Signal Transducers and Activators of Transcription 
TEC  Thymic medullary Epithelial Cells 
TRPC  Transient Receptor Potential non-selective ion Channels 
V2R V2 Vasopressin Receptor 
WT Wild Type 
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Introduction 
G-proteins and G-protein Coupled Receptors  
 
Any biological organism processes enormous 
amounts of data to survive and to adapt to the 
environment. Cells perceive the presence of 
nutrients, noxious agents, hormones, etc. by 
recognizing extremely heterogeneous arrays of 
external stimuli (including light, ions, peptides, 
sugars, lipids) and in many cases can follow the 
stimulus by trailing its concentration gradient. 
This implies the ability to detect the direction 
from where the “signal” originates and therefore, 
not only an integration of the information in three 
dimensions, but also an integration over time 
while moving toward a target or, as opposite, 
while stirring away from a repellent agent. 
 
In multicellular organisms, communications 
evolved and became reciprocal. Stimuli are 
transmitted from one cell to another thanks to 
“ligand molecules”. The ligand produced by a 
cell is set free to diffuse and specifically 
recognize transmembrane receptors on target 
cells. Receptors are molecules specifically 
committed to recognize a stimulus and to transmit 
its signal across the plasma membrane. The 
passage of information across the plasma 
membrane in most cases already implies a first 
Figure 1 - “GPCR Topology”: GPCR 
aminoacidic sequence typically includes 
seven hydrophobic alpha-helices that 
create seven transmembrane domains. 
This arrangement  produces an 
extracellular N-terminus often 
glycosylated, three extracellular loops 
(EC), three intracellular loops (IC) and a 
fourth loop created by the palmytoylation 
of cysteine residues that become an 
anchor for the C-terminus. In most cases 
the C-terminus is particularly enriched in 
serines and threonines. A disulphide 
bridge usually links two cysteines present 
in EC 1 and EC2. 
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integration of the information (see below). 
 
G-protein-coupled receptors (GPCRs) represent the largest family of proteins accounting for 
over 800 distinct genes, that correspond to more than 1% of the human genome and almost 3% 
of the proteome (Fredriksson et al., 2003; Vassilatis et al., 2003). GPCRs are expressed by 
almost all living organisms including fungi and viruses. It has been estimated that each 
individual eukaryotic cell expresses mRNA for perhaps over 100 different GPCRs (Hakak et al., 
2003; Tang and Insel, 2004). 
The members of this family of proteins mediate most of the signal transduction occurring across 
the plasma membrane. GPCRs not only respond to hormones, growth factors, neurotransmitters 
and chemokines but also respond to sensorial stimuli of sight, smell and taste. In order to mediate 
such a diversified number of tasks, specific GPCRs evolved to respond to structurally very 
diverse ligands including: peptides (chemokines, vasopressin, bradikinin, etc.), lipids 
(prostaglandin, tromboxane, lysophosphatidic acid, etc.), glycoproteins (follicle-stimulating 
hormone, thyroid-stimulating hormone, glucagon,etc.) aminoacids (glutamate, histidine,etc.) and 
their derivatives like bioamines (adrenalin, dopamine,etc.), ions (calcium and protons), photons 
(exciting retinal), aromatic molecules (odorant receptors), etc. 
GPCRs are involved in the regulation of virtually all physiological functions. In the periphery of 
our organism, they modulate endocrine or exocrine secretion, pain transmission, smooth muscle 
and cardiac contraction, fluid homeostasis, blood pressure, immune response etc. In the central 
nervous system GPCR regulate body temperature, behavior, satiety, sleep, etc.  
 
The development of a novel organism is likely the moment when cell-cell communications 
become more dynamic. Cells migrate from one district to another proliferating or dying in a 
coordinated fashion leading to the marvelous complexity of the entire organism. GPCRs like 
Frizzled (in the Wnt/catenin pathway) and Smoothened (in the Hedgehog pathway) are 
determinant key-factors in “cell development”. In many cases, the same receptor involved in the 
formation of the organ remains functional after cell differentiation is completed and in the adult 
cell it acquires tissue specific functions. A good example is represented by olfactory receptors. 
Each olfactory sensory neuron expresses a single olfactory GPCR after silencing several 
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hundreds homologs. It is this same GPCR that, trailing a still undefined chemotactic signal, 
drives the projection of the axon to a specific glomerulus in the olfactory bulb. In such 
glomerulus converge all, and only, projections of olfactory sensory neurons expressing the same 
GPCR (Mombaerts, 2004). As a result, in adult life, all olfactory neurons sensing a specific 
molecule will project to the same glomerulus. 
 
The plethora of biological functions combined to the potential for pharmacological intervention 
intrinsic to the specificity of the ligand-receptor interaction (usually in the range of the low 
nanomolar) generated considerable interest in the mechanisms by which GPCRs exert their 
function. Not surprisingly, GPCRs are today the most successful pharmaceutical target and more 
than 30% of prescribed drugs are molecules that simulate or prevent natural GPCR ligands 
(Rozengurt, 2007c). This quota represents approximately 9% of global pharmaceutical sales 
(Rovati et al., 2007). However, therapeutic drugs act only on less than 40 distinct GPCR leaving 
a tremendous potential for drug discovery applied to this superfamily of proteins. 
 
 
GPCR conformations 
 
All GPCRs share a common molecular topology spanning seven times the plasma membrane 
(Figure 1). Typically, the interaction of the ligand with the extracellular domains triggers a 
conformational change that is transferred to the receptor intracellular domains and, on turn, 
specifically activates intracellular interactors. GPCRs derive their name by their ability to act as 
guanine nucleotide exchange factors (GEFs) for heterotrimeric (α, β, γ) G proteins (Figure 3). 
The occupied receptor thereby promotes the exchange of GTP for GDP in the alpha subunit of 
the G protein and, as a consequence, the activation of "downstream" signalling components. 
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Mammals express 16 distinct α subunits genes grouped in four classes according to sequence 
similarity and effectors regulation:  
- Gq class components activate phospholipases (PLCs) to hydrolyze phosphatidylinositol (4,5)-
bisphosphate (PIP2) to diacylglycerol (DAG) and inositol (1,4,5)-trisphosphate (IP3).  
- Gs class components activate adenylyl cyclases (AC) to increase the concentration of cAMP. 
- Gi class components inhibit AC. 
Figure 3 - G-protein cycle of activation: In the heterotrimeric form (α, β and γ subunits), G 
proteins are inactive with the α subunit bound to GDP. Active GPCRs act as exchange 
factors (GEF) favoring the release of GDP in exchange for GTP and the consequent 
separation of the βγ subunit. βγ acts therefore as guanine nucleotide dissociation inhibitor 
(GDI). Once separated, α and βγ subunits are now free to interact with their downstream 
effectors. The hydrolysis of GTP is catalyzed by proteins acting as Regulators of G protein 
signalling (RGS) also named GTPase Activating Proteins (GAP). The α subunit remaining 
bound to GDP associates again to the βγ subunit returning to the inactive state. 
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- G12 class components activate small GTPases (i.e. RhoA). 
The released βγ subunit displays also functional activity. The identity of the components of the 
dimer determines which downstream effectors becomes activated (Birnbaumer, 2007). 
GPCRs are remarkably versatile signalling molecules. An individual GPCR can signal through 
several G protein subtypes or even activate G-protein independent pathways (Lefkowitz and 
Shenoy, 2005; Brzostowski and Kimmel, 2001). This functional plasticity is likely due to their 
structural flexibility that allows each receptor to assume alternative specific conformations. 
Initially, GPCR have been described as bimodal switches shifting from the “off state” to the “on 
state” in response to the interaction with the ligand. Accordingly, less effective agonists (partial 
agonists) were believed to vary in signal strength, nonetheless, all agonists were assumed to 
qualitatively reproduce the same effect as the endogenous agonist(s). 
A similar scenario may apply to rhodopsin, with basal signalling virtually silent until the 
absorption of a single photon of light induces maximal activation. However, in many cases, 
GPCRs display significant levels of spontaneous activity. The extent of basal activity can be 
enhanced by single-point mutations in various structural domains. In several cases, mutations 
that disrupt the interactions between transmembrane domains also increase the ‘flexibility’ of the 
protein (movement of transmembrane domains relative to each other) and thus the probability 
that the receptor can assume an active conformation. Some of the best-characterized examples of 
constitutively active mutants (CAMs) are those that disrupt the highly conserved 
(D/E)R(Y/W/H) amino acid sequence (also called DRY motif) present in 72% of GPCRs 
belonging to the rhodopsin family (http://lmc.uab.cat/gmos/). This motif forms non-covalent 
interactions with the cytoplasmic end of the sixth transmembrane domains creating the so-called 
“ionic lock”, which stabilizes the receptor in the basal state. The disruption of this network of 
interactions by mutating the DRY motif was shown to lead to constitutive activity (spontaneous 
activation) (Kobilka and Deupi, 2007).  
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Spectroscopic studies on purified receptors (Kobilka and Deupi, 2007) have also suggested that 
agonist binding and activation occur through a series of conformational intermediates. Possibly, 
the binding of structurally different agonists entails the disruption of specific combinations of 
intramolecular interactions. On the intracellular side, also the G protein in some cases was 
proven to interact with the inactive receptor (Figure 4) contributing to modify the conformation 
and the affinity of the receptor for the ligand (Birnbaumer, 2007). Therefore, at any time, 
agonists and intracellular direct interactors simultaneously contribute to shape the receptor 
Figure 4 - GPCR pharmacological models - Free agonists (A) bind to the receptor (R) that 
on turn interacts with the G protein (G). All interactions follow the law of mass action (K1, 
K2, L, M = equilibrium dissociation constants). (a) 1980: 'Ternary complex model' by De 
Lean et al. (De Lean et al., 1980). Agonists bind to the receptors (R) and the (AR) complexes 
bind to G proteins to form active ternary (ARG) complexes. (b) 1993: 'Extended ternary 
complex model' by Samama et al. (Samama et al., 1993). Receptors must undergo a 
conformational transition from the basal, inactive state (Ri) into the active state (Ra) to bind 
to, and activate G proteins. Agonists favor this transition but it can also occur spontaneously. 
To be a true two-state model, α and β must be equal to 1. (c) 1996: 'Cubic ternary complex 
model' by Weiss et al. (Weiss et al., 1996). In this model are contemplated non-signalling 
complexes formed by inactive receptors and G proteins. Actually, the latter model is further 
expanded by biased agonism theories (see text). 
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conformation shifting the equilibrium of coexisting different states. In the model described 
above, agonists or the inverse agonists re-modulate the quotes of the different conformations. As 
a result, the message is transferred through the signalling network reducing or increasing the 
activity of effectors associated to one conformation or another, with the final result of producing 
a well defined physiological impact. This model could explain how most GPCRs simultaneously 
activate multiple signalling cascades sometime even bypassing the same G-protein (Brzostowski 
and Kimmel, 2001). In addition, the model explains how the final perturbation elicited by an 
agonist may depend on the intensity of the stimulation, not only in quantitative terms, but also 
qualitatively (Sun et al., 2007). 
 
The existence of alternative activation states could explain paradoxes described for decades in 
pharmacology literature. For instance, the fact that different ligands for a given GPCR can show 
different efficacy profiles when distinct signalling pathways are compared (Kenakin, 2003; 
Kobilka and Deupi, 2007), in other words, different functional responses described by dose-
response curves are not necessarily comparable when the ligand changes.  
Another aspect that can be explained by the existence of distinct GPCR conformations is the 
existence of partial agonists, which, as mentioned above, are ligands that cannot produce the 
same maximal effect of a full agonist (even once all available receptors are occupied). 
 
 
The complexity of the transduction process 
 
During the normal life of a cell, dozens of different receptors are active at any given moment. As 
a result, multiple signals depart the plasma membrane to travel inside the cell. The diffusion of 
the signal occurs through shared effectors converging on a relatively limited number of common 
knots (Figure 5). The activation scheme is further complicated by the fact that GPCR can 
oligomerize. Compelling evidence shows in fact that omo- or hetero- dimers form in vivo (Park 
et al., 2004). Yet, besides very few exceptions, it remains obscure how the partners influence 
each other signalling properties. 
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Figure 5 - Highly generalized scheme of the “network” of transduction pathways 
activated by GPCRs –This figure is an attempt to exemplify the most recurrent functional 
relationships among the major classes of signalling molecules. The arrows are representative 
of activatory (green) or inhibitory (red) interactions. Almost a thousand GPCR isoforms 
signal through a relatively limited number of highly shared effectors such us 16 Gα subunits, 
2 non visual arrestins, 7 GRK. 
The entire human “kinome” is estimated to comprehend approximately 500 members 
(Manning et al., 2002), usually a stimulus travels through the cytosol by branching 
sequences of phosphorylatory events and an apparently very limited number of second 
messengers. As a result, the signal converges on common knots often shared with other 
receptor types, like tyrosine kinase receptors. 
GPCRs can utilize different scaffolds to activate the small G-protein/MAPK cascade, 
employing at least three different classes of Tyr kinases: 
1) Src family kinases are recruited following activation of PI3K by βγ subunits. They are 
also recruited by receptor internalization, 2) cross-activation of receptor Tyr kinases, 3) 
signaling through an integrin scaffold involving Pyk2 and/or FAK. GPCRs can also employ 
PLCβ to mediate activation of PKC and CaMKII, which can have either stimulatory or 
inhibitory consequences for the downstream MAPK pathway. 
It remains largely unclear how so many receptors process meaningful information by acting. 
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It remains largely unclear how so many receptors process meaningful information by acting 
simultaneously through such a small number of effectors. How many G proteins are required to 
sort the appropriate response to a ligand? Is spatial organization of the molecules (enzymes, 
second messengers,etc.) what establishes autonomous circuits and therefore specificity? How 
does the signalling of each receptor adapt to different types of cell differentiation? All these 
questions are just beginning to be answered as technology develops the tools with the necessary 
resolution. For the moment however, earlier models of signalling cascades created by linear 
chains of interactions between exclusive partners appear today inadequate. 
 
The regulation of the heartbeat, the modulation of synaptic transmission, a neutrophil chasing a 
bacterium in the bloodstream are just some examples of the final effect of coordinated GPCR 
activation. Though we begin to understand which factors are involved in transducing the signal 
we are likely still missing “the syntax”. The emerging picture sees GPCR activation far more 
complicate than molecular pharmacologists imagined a decade ago. Rather than switches, may 
be receptors should be depicted more like the keys of a piano. Like single notes played 
simultaneously and timely generate music, a network of harmonic coordinated signals is likely 
produced once a GPCR agonist reaches the cell surface, and in the next paragraph we will see 
how the intensity and duration of the stimuli is also taken into account and integrated by these 
molecules. 
 
 
GPCR regulation over time 
 
GPCR stimuli are almost never presented to the cell as an “all or nothing” event, rather, the cell 
has usually to track continuous variations of the intensity of the stimulus. For example, a 
principal cell, determining how much water the kidney should recover by concentrating urine, is 
regulated by variation of the concentration of the antidiuretic hormone in the blood; the glucose 
receptor in yeast continuously monitors the sugar concentration in the environment, etc. 
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Over time, cells finely tune receptor efficiency by matching the cellular responsiveness to the 
intensity of the stimulation. Even when the concentration of the stimuli varies by many logs, an 
appropriate response can be obtained adjusting the sensitivity threshold. One example is 
represented by cells following gradients of stimuli such as leukocytes chasing bacteria or 
migrating toward the inflammation site while trailing chemokine signals. 
Figure 6 - GPCR Regulation - Schematic representation of the steps leading to GPCR 
desensitization, internalization and recycling. 1) Free GPCR is recognized by the cognate 
ligand. 2) The occupied receptor activates the G protein. 3) GRK is targeted to the plasma 
membrane by the interaction of its PH domain with βγ. Simultaneously, it recognizes the 
activated GPCR and catalyzes its phosphorylation on multiple sites. 4) The receptor is 
recognized by arrestin that binds to it and obstructs further interaction with the G protein. 5) 
The complex receptor-arrestin binds to other adaptors (AP2, NSF) and is recruited to clathrin 
coated pits. 6) GPCRs are endocytosed in early endosomes from where they can be targeted 
either to 7a) recycling compartments and from there back to the plasma membrane, or to 7b) 
lysosomes for degradation. 
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An efficient regulation of the receptor potency is crucial not only under normal conditions, but 
also under pharmacological treatment of many diseases when GPCR agonists typically produce 
prolonged stimulation. 
 
The process by which repeated or prolonged stimulation progressively reduces receptor 
efficiency and sensitivity is defined as “desensitization” and it includes regulatory mechanisms 
acting directly on the GPCR. 
 
Within seconds of becoming occupied by the agonist and activating the G-protein, the receptor 
becomes phosphorylated by kinases named GPCR kinases (GRKs) (Figure 6). GRKs are 
activated by their own substrate, the occupied receptor. For this reason GRK activity is defined 
as homologous phosphorylation as opposed to the heterologous phosphorylation mediated by 
kinases activated by 2nd messengers (PKA and PKC). In the latter case, the substrate is not 
necessarily the same receptor that triggered the signal but can be another GPCR (ligand free) 
even of a different subtype. Normally the phosphorylation level is proportional to the number of 
receptors occupied by the ligand and remains sustained as long as the ligand is not removed 
(Innamorati et al., 1997). However in rare cases, the phenomenon is transient and rapidly 
declines even in continuous presence of saturating concentrations of ligand (Innamorati et al., 
1998).  
GRK phosphorylation usually occurs on multiple serines and threonines usually all located in the 
carboxyl terminal cytoplasmic tail. Over a threshold of 2-3 phosphate groups per receptor, 
phosphorylation promotes the interaction with a second class of proteins, named arrestins. Like 
the G proteins and GRKs, two ubiquitous arrestins recognize hundreds of GPCRs conditionally 
to their activation state (other two arrestin isoforms are specifically expressed in the retina). The 
interaction with arrestin interdicts the interaction with the G-protein and therefore limits the 
duration of G-protein signal by steric exclusion (Lefkowitz, 2007). β-arrestins also scaffold 
receptors to the membrane-trafficking machinery (NSF, AP-2, clathrin, sorting nexins,etc.) 
promoting receptor recruitment to coated pits and its internalization away from the cell surface 
and from G proteins. The rate of internalization can vary depending on the number and type of 
receptor. GPCR structural heterogeneity likely modulates the relative affinity for endocytic 
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adaptors (Yang and Xia, 2006) and therefore the intracellular routing followed by endocytosed 
receptors via multiple endocytic mechanisms, including caveolae. The same stability of the 
interaction with arrestin depends on the number and the pattern of phosphorylated sites; it 
therefore varies depending on the GPCR taken into consideration (Oakley et al., 2001). Arrestin 
can detach with clathrin just upon the vesicle is released from the plasma membrane, otherwise it 
can follow the receptor while trafficking to endosomal compartments (Innamorati et al., 2001). 
The physiological role played by the concerted action of GRKs and arrestins in maintaining 
appropriate levels of GPCR signalling has been documented by transgenic and knockout animals 
(Premont and Gainetdinov, 2007). It should also be mentioned that while β-arrestins turn off G-
protein coupling, they simultaneously turn on other sets of signals scaffolding numerous 
signalling molecules (such as MAPKs, Src) (Lefkowitz et al., 2006). The time extent of the 
interaction is likely to have important implications in this context. What described above, was 
mostly discovered studying the activation of “prototypical” GPCRs, such as the β2 adrenergic 
receptor (β2AR) and the V2 vasopressin receptor (V2R), that display very low spontaneous 
activation. 
However, other GPCRs with higher spontaneous activity show tonic phosphorylation also in the 
absence of the ligand, possibly correlated to a higher basal turn-over (Innamorati et al., 2006). 
 
 
Constitutive receptor activity and constitutive desensitization  
 
As reported above, GPCRs can display robust constitutive activity due to their spontaneous 
activation or to activatory mutations in the case of CAMs. In some cases, such ligand 
independent activation is associated to the phosphorylation of the receptor and to a reduced 
efficiency. The effect of the mutation is however difficult to reconcile with a model accounting 
for only two receptor conformations (active and inactive). Most likely also the desensitization 
process is calibrated depending on the conformation of the receptor. An emblematic example is 
the V2R. 
The substitution to cysteine or leucine of the central arginine of the DRY motif (DRH in the 
V2R) produces a mutant that displays higher activity as compared to the wild type (WT). As a 
result, patients carrying these mutations are affected by “nephrogenic syndrome of inappropriate 
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antidiuresis” (Feldman et al., 2005). These individuals concentrate urine as under the intense 
effect of the antidiuretic  hormone Arg-Vasopressin (AVP) that exerts its antidiuretic action by 
binding to the V2R. However, the effect is due to the constitutive action of the receptor since in 
the blood AVP is virtually absent due to the hyponatrimia that induces the hypophisis to block its 
release. 
As opposite, the substitution to histidine of the same arginine, stabilizes the receptor in a 
conformation that remains stably associated to β-arrestin (Barak et al., 2001). Because of the 
enhanced arrestin function, the V2R-R137H is substantially incapable of activating the natural 
V2R effector, Gs, and adenylyl cyclase as demonstrated by heterologous expression in HEK-
293T (Barak et al., 2001) and L- (Rosenthal et al., 1993) cells. Consistently, patients carrying the 
R137H mutation suffer of nephrogenic diabetes insipidus, manifesting the same symptoms of 
patients carrying V2R mutations that prevent the synthesis of a functional receptor or its 
expression to the cell surface. 
 
 
GPCR mediated mitogenic signalling 
 
The cells of multicellular organisms must efficiently communicate with each other to coordinate 
and integrate their functions, including their reproduction. GPCRs agonists of different nature 
(aminoacidic, peptidic, lipidic,etc.) can act as potent cellular growth factors and relay mitogenic 
signals to the nucleus promoting cell proliferation. 
Consistently, heterotrimeric G proteins have been implicated as mitogenic signal transmitters. 
The discovery of activating G protein mutations in various disease states highlights their roles in 
normal and aberrant growth (Vallar, 1996). To date, a number of G proteins subunits have been 
shown to stimulate mitogenesis and to induce neoplastic growth via initiation of intracellular 
signalling cascades that lead to the activation of transcription factors (Figure 7). Several 
intracellular effectors are responsible for creating the connection the nucleus. The best 
characterized regulators of DNA transcription are likely mitogen-activated protein kinases 
(MAPKs) (Dorsam and Gutkind, 2007). In addition, other critical molecules, such as signal 
transducers and activators of transcription (STATs), have been shown to participate in the 
Introduction 
 
 
17 
 
transduction of proliferative signals (Ram et al., 2000). STATs were also reported as substrates 
of MAPKs. Intermediate steps in these signalling cascades include phospholipases (A2, C, D), 
small GTPases (Ras, Rho,etc.), kinases (Src, focal adhesion kinases (FAK), protein kinase C 
(PKC)) (Chiu and Rozengurt, 2001). As a first step, many mitogenic GPCR agonists activate 
Gq/11 family members. Four members of the Gq/11 subfamily (Gαq, Gα11, Gα14, and Gα15) 
couple GPCR to inositol lipid signalling via phospholipase C-β isozymes 1-4 (PLC-β1-4) and 
other protein binding partners (Hubbard and Hepler, 2006). Activated Gα subunits stimulate the 
enzymatic activity of PLC-β (Rhee, 2001). As a result, the breakdown of the membrane lipid 
phosphatidylinositol (4,5)-bisphosphate (PIP2) produces second messengers inositol (1,4,5)-
trisphosphate (IP3) and diacylglycerol (DAG). 
The Gβγ subunit is also active on PLC isoforms (PLCβ2 and PLCβ3), the lower affinity, is 
compensated by the large abundance of Gi in many cellular membranes that makes “Gi coupled 
receptors” also effective activators of PLC. IP3 binding to specific receptors on the endoplasmic 
Figure 7 - GPCR mediated mitogenic signalling. This scheme summarizes the best 
described signalling pathways triggered by GPCRs and leading to the nucleus. Signalling 
mediated by PLC and Ras converge on MAPKs aimed to regulate cell cycle. 
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reticulum (ER) produces the release of large quantities of Ca2+ that are rapidly reabsorbed 
producing the typical transient increase. The depletion of the intracellular ER stores on turn 
triggers the opening of plasma membrane Ca2+ channels leading to the long-lasting plateau phase 
determined by the influx of extracellular ions. This process is known as “store-operated Ca2+ 
entry” (SOCE) and it is relevant to mitogenic stimuli (Charlesworth and Rozengurt, 1994). 
SOCE molecular bases remain poorly understood, in particular, it is still unclear how the 
depletion of the ER stores is sensed and transmitted to the plasma membrane. STIM is a ER 
resident protein strongly suspected to be the Ca2+ sensor (Liou et al., 2005; Roos et al., 2005; 
Lopez et al., 2008) while the strongest suspects on the plasma membrane are the transient 
receptor potential non-selective ion channels (TRPC) (Smyth et al., 2006) and the tetra-spanning 
Orai. 
 
Sub-maximal GPCR stimulations are most of the time associated to oscillatory Ca2+ 
concentration, the frequency of the waves is proportional to the intensity of the stimulus (agonist 
concentration) and strongly depends on extracellular ions. SOCE is therefore responding to 
GPCR occupancy in a very coordinate manner transforming the message carried by the agonist 
in Ca2+ waves. Frequency and amplitude of the waves can regulate gene transcription and cell 
proliferation in a very precise manner. Calcium signalling can therefore be considered as a yet 
undeciphered language utilizing a syntax based on periodical variations of Ca2+ concentration. 
 
DAG also contributes to mitogenic signals. Exogenously added to Swiss 3T3, it is sufficient to 
promote cell division (Rozengurt et al., 1984). DAG best established target is PKC, a regulatory 
domain interacts directly with DAG in all “novel” PKC isoforms (δ, ε, η, θ) and in all “classic” 
(α, β, γ) isoforms where it synergizes with Ca2+  binding to a distinct region (Rozengurt, 2007c). 
DAG effect can be stimulated by phorbol esters like PMA that are also potent carcinogens. 
 
PKC involvement in the regulation of cell proliferation is very well established including for 
stimuli generated by GPCRs. Its effect can promote or inhibit cell proliferation or survival 
depending on the isoforms and on the context. 
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As the signal travels from the plasma membrane toward the nucleus, many other effectors 
become involved, not only strictly providing the connection but also integrating and modulating 
it. 
PKD (a PKC related kinase activated by DAG and PKC phosphorylation) can act prolonging the 
duration of GPCR signalling (bombesin and AVP receptors) via MAPK (MEK→ERK→p90RSK 
(Rozengurt, 2007b)) aimed to promote DNA synthesis and cell proliferation in Swiss 3T3 cells. 
In fact, shortening sustained ERK activation prevents the effect on DNA synthesis. By 
modulating the time of the stimulation, PKD is therefore crucial to define gene products induced 
by GPCR activation. A number of scaffolding proteins and inhibitors is being discovered, these 
key-factors are likely responsible for making the stimulation more rapid, potent, specific or for 
modulating its duration. 
For instance, PKC and PKD can relieve the action of inhibitors, like RKIP (Raf kinase inhibitor 
protein) and RIN1 (Rab Interactor 1) respectively (Wang et al., 2002), synergizing with other 
pathways.  
RKIP and RINI phosphorylation by PKC sets Raf free from the inhibitor that relocate its action 
to GRK thus preventing GPCR homologous desensitization (Lorenz et al., 2003). 
 
Cytosolic β-arrestins translocate on the plasma membrane to scaffold MAPKs to the stimulated 
GPCR once they have been initiated to the desensitization process (see page 12). In addition, β-
arrestins have nuclear localization signals. In the case of β-arrestin1, this ensures nuclear and 
cytosolic distribution. In the case of β-arrestin 2, a prevailing nuclear export signal prevents 
nuclear accumulation (Scott et al., 2002). Massive GPCRs activation can deplete 
cytosolic/nuclear arrestin inducing the massive redistribution of MAPKs (Scott et al., 2002; 
Tohgo et al., 2003). Despite the astonishing number of interactions revealed so far, the role of 
arrestin in carcinogenesis remains elusive and could go beyond cell proliferation. Arrestin 
promoted ERK activity has been involved in cell migration and chemotaxis (Ge et al., 2004) and 
PGE2-induced metastasis in colon cancer cells (Buchanan et al., 2006). 
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As in any other physiological response triggered by GPCR, the pathways promoting cell 
proliferation are extensively interconnected by synergistic and antagonistic cross-talks. PLCβ2 
and PLCε are activated by small GTPases (Rho, Ras) (Bunney and Katan, 2006).  
The signal can also take less conventional paths, after crossing a first time the plasma membrane 
via GPCR, it can cross back exiting the cell to re-enter by activating tyrosin kinase receptors like 
the EGF receptor in a process named transactivation. GPCR effectors in fact activate 
metalloproteases (ADAM family) that cleave precursor forms of EGF, TGF-α, amphiregulin 
(Rozengurt, 2007a). Transactivation can also occur intracellularly or possibly by direct 
interaction between the receptors (Buchanan et al., 2006; Hunyady and Catt, 2006). In distinct 
cell types, transactivation mediates GPCR induced Ras->Raf->MEK->ERK->p90RSK and 
PI3K->Akt activation (Santiskulvong et al., 2001; Santiskulvong and Rozengurt, 2003; Chiu et 
al., 2005). Transactivation may therefore contribute to explain how GPCRs control cell cycle 
progression. 
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G15 
 
G15 is a heterotrimeric G protein member of the Gq class, that also includes Gq, G11 and G14. 
Because of its restricted distribution and because of its peculiar signalling characteristics G15 is 
probably the most peculiar member of the Gq family. 
 
 
G15 distribution 
 
Among Gq class members, Gαq and Gα11 are ubiquitously distributed across tissues as they 
have been detected in every screened cell type (Hubbard and Hepler, 2006). However in a few 
cases one of the two prevails: differential expression was observed in certain T-cells types and 
other leukocytes while platelets selectively express Gαq but not Gα11. The other Gq family 
members, G15 and G14, have a much more limited distribution. The tissue expression pattern of 
Gα15 has been widely reported as the most restricted. An initial characterization of Gα15 
distribution was based on cell lines and depicted a profile limited to cell types of hematopoietic 
origin (Amatruda, III et al., 1991). Further analysis localized Gα15 to tissues that are rich in 
hematopoietic cells (Wilkie et al., 1991). In lymphoma patients undergone to chemotherapy, 
Gα15 mRNA expression was associated to the presence of CD34 antigen during hematopoietic 
recovery (Pfeilstocker et al., 2000). CD34 antigen is a reliable surface marker for quantification 
of hematopoietic cells but its mRNA expression is restricted to the Go phase (quiescent cells) 
(Pfeilstocker et al., 2000). By contrast, Gα15 mRNA is expressed independently of cell cycle 
stage. In particular, Gα15 is enriched in cells in the earlier stages of differentiation. Various 
myeloid and lymphoid cells in the progenitor stages express Gα15 at high levels, but these levels 
decrease sharply as the cells become differentiated (Tenailleau et al., 1997). Gα15 is down 
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regulated also during megakaryocytopoiesis (den Dekker et al., 2001), however, in one report, 
Gα15 was found in the cytosolic fraction of platelets enriched of secretory granules (Giesberts et 
al., 1997). In HL60 cells, Gα15 expression is downregulated during terminal differentiation 
induced by dimethyl sulfoxide as the cells acquire morphological features characteristic of 
neutrophils and lose the ability to proliferate (Amatruda, III et al., 1991). 
Under very specific circumstances Gα15 expression is restored, i.e. upon activation of quiescent 
blood lymphocytes in T (Lippert et al., 1997) and likely in B (Rosskopf et al., 2003) cells, as 
previously suggested by the presence of Gα15 mRNA in human B lymphoblast cell lines derived 
from peripheral blood lymphocytes and immortalized with Epstein-Barr virus (Rosskopf et al., 
2003).  
 
 
G15 signalling 
 
Gq class members share functional abilities but exhibit limited amino acid sequence identity. 
Overall identity is only 57% (compared with 90% for Gs and 85% for Gi) that gets to 30% 
within the first 40 amino acids. As compared to Gαq, Gα11 is 83% identical in this region while 
for Gα14 and Gα15 this value decreases to only 65% and 35% respectively. The extensive 
sequence diversity of Gα14 and Gα15, suggests that these proteins may be functionally divergent 
from Gαq and Gα11, or at least may be regulated by different biochemical mechanisms. 
G15 restricted expression pattern suggests tissue-specific signalling functions. Consistently, 
Gα15 expression has been shown to be important for multiple aspects of hematopoietic 
physiology including erythroid differentiation and T-cell activation (Lippert et al., 1997; Ghose 
et al., 1999). In particular, G15 was demonstrated to play a role in regulating TCR/CD3-induced 
production of two important cytokines, IL-2 and IL-10 (Zhou et al., 1998). G15 signalling could 
be associated to intense cellular expansion (activated T and B cells). Accordingly, the 
downregulation or upregulation of G15 functional activity affected growth rates and 
differentiation of human erythroleukemia cells, a model of erythroid differentiation. 
 
However, knock out approach demonstrated that in mice Gα15 can be dispensed under normal 
conditions. Transgenic mice are in fact viable and fertile. Furthermore, Gα15 -/- mice show 
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normal hematopoiesis. In ex-vivo experiments, macrophages derived from these mice were 
challenged with GPCR agonists considered to couple to G15 in vivo: C5a, UTP, PAF. Inositol 
phosphate production and Ca2+ mobilization were affected only in the case of the anaphylatoxin 
C5a, with a partial reduction of the responses (likely simultaneously supported also by Gi 
(Davignon et al., 2000a)), the effects of chemokines on Ca2+signalling in myeloid cells are in fact 
largely PTX-sensitive and therefore mediated by Gβγ derived from resident Gi rather than G15 
(Offermanns and Simon, 1995; Vanek et al., 1994; Baggiolini and Clark-Lewis, 1992).  
G15, and to a lesser extent G14, exhibit a surprising ability to couple to GPCRs that are not 
reported to be naturally linked to inositol lipid signalling. Followed by many other GPCR, Gi/o-
linked C5a chemotactic receptor (C5aR) was the first one shown to couple to recombinant G15 
(Amatruda, III et al., 1993; Buhl et al., 1993) in mammalian cells. A number of receptors (β2 and 
α1b adrenergic, M2  muscarinic, V2 AVP, D1 dopamine, adenosine A, serotonin, opioid, various 
chemotactic receptors and metabotropic glutamate receptors just to cite a few) have been found 
to interact promiscuously with Gα15 when reconstituted into COS-7 cells (Offermanns and 
Simon, 1995; Zhu and Birnbaumer, 1996). Despite such high promiscuity, some degree of 
specificity persists. The receptor promiscuity of G15 is in fact less apparent when co-transfected 
with the α1a and α1d adrenergic receptors that couple to other G-proteins but not to G15 
(Hubbard and Hepler, 2006; Xie et al., 1997) or some C-C chemokine receptors although 
normally co-expressed with Gα15  (Arai and Charo, 1996; Kuang et al., 1996). 
Given their role in hematopoiesis, chemokine receptors are traditionally considered the most 
likely upstream activators of G15 signalling, however, it is quite possible that GPCRs other than 
chemokines receptors are the main activators of G15 signalling in vivo. As a matter of fact, 
chemokine receptors are expressed at the highest levels in mature cells (Hubbard and Hepler, 
2006) while, as mentioned above, Gα15 is highly expressed in progenitor cells and decreases 
during differentiation (Amatruda, III et al., 1991) as shown in HL-60 cells (Perez et al., 1992; 
Boulay et al., 1991; Minisini et al., 2003). Many other GPCRs could act via G15. Hematopoietic 
cells expresses hundreds of them, including the δ opioid (Steidl et al., 2004) (DOR) and the β2 
adrenergic (Muthu et al., 2007) (β2AR) receptors. A number of signals could thus be amplified 
by this G protein including exogenous and constitutively active forms of pUS28, a human 
cytomegaloviral protein that encodes a chemokine-like GPCR, that was shown to induce ligand-
independent, pertussis toxin-insensitive inositol lipid signalling, presumably mediated by Gα15 
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(Kostenis et al., 1997; Billstrom et al., 1999; Minisini et al., 2003). G15 could therefore become 
relevant under pathological conditions. 
 
Owing to its promiscuity, G15 has been widely exploited to reveal the signalling of GPCR by a 
still unknown downstream pathway. Typically, this occurs in the case of orphan receptors (i.e. 
genes that have the characteristics of a GPCR but it is still unknown to which ligand/s they bind). 
Pharmaceutical research has developed high throughput screenings for potential ligands utilizing 
cells cotransfected with an orphan receptor and G15 as a platform in which [Ca2+] or IP3 
accumulation can be measured as a read out. 
 
When G15 level of expression was induced to “physiological” levels, promiscuous coupling was 
still observed (Offermanns et al., 2001) but hardly any data is available in endogenous systems. 
 
 
Specificity determinants on G proteins.  
 
The molecular bases allowing G15 broad specificity are still elusive. 
Generally speaking, the GPCR–G-protein interface must encode important information to 
determine which G proteins can interact with a particular receptor but, despite many of the 
contact sites at the interface have been mapped, the connections that define coupling selectivity 
remain unclear. 
Upon activation, the receptor opens a cytosolic pocket for the Gα C terminus (Oldham and 
Hamm, 2008). C-terminal chimaeras of Gα subunits have been frequently used to switch 
receptor–effector coupling (Kostenis et al., 1997). 
Two domains in Gα15 C-terminus are unique among Gαq family members and contribute to 
coupling, however, transferring these sequences into Gα11 failed to link Gα11 to C5aR unless 
additional upstream sequences were relocated (Lee et al., 1995). Other poorly defined N-terminal 
Gα15 sequences are also sufficient for promiscuous receptor interaction (Lee et al., 1995). Taken 
together, these studies indicate that various discrete regions of Gα15 independently contribute to 
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the non-selective coupling. If multiple regions on Gα15 confer capacities for promiscuous 
receptor coupling, probably it is only the subtle cooperation of multiple interactions that 
produces the correct selectivity. 
 
In addition to the structural determinants on Gα other understudied factors could contribute to 
define the specificity of the interaction. Specific isoforms of Gβ have been shown to interact 
preferentially with specific receptors and in some cases the composition of the βγ subunits may 
preclude Gα binding to the receptor (Birnbaumer, 2007). Finally, other factors like the type of 
lipid modification could influence the affinity for the receptor (see γ geranygeranylation as 
compared to farnesylation). 
 
 
Specificity determinants on GPCRs 
 
Much of the difficulty in understanding coupling specificity between receptors and G proteins 
arises from the poor sequence homology of the intracellular loops that comprise the G protein 
binding site. Even closely related receptors that activate the same G protein can have dissimilar 
ICLs, making it impossible to determine coupling based on primary structure alone. Extensive 
studies have shown that IC2 and IC3 (see figure 1) are the most common selectivity determinants 
in receptors, although IC1 and IC4 can occasionally intervene. Frequently, mutations in other 
regions of the receptor (distant from the G protein binding site) can affect coupling, which 
suggests that the global conformation of the receptor or changes in its dynamics may be just as 
important as specific side chain interactions in determining receptor–G-protein selectivity 
(Oldham and Hamm, 2008). The α1b adrenergic receptor has been extensively mutagenized in 
order to define the molecular determinants driving the interaction of Gα15. However, only the 
deletion of half of the second intracellular loop could effectively prevent the interaction (Wu et 
al., 1995). Given the extent of the deletion, concerns raise about the integrity of the overall 
receptor conformation.  
As opposite, CCR2A and CCR2B are two alternative splicing variants and they differ only in 
their C-terminal intracellular domains. However, only CCR2B is coupled to G15 in transfected 
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COS-7 cells (Kuang et al., 1996). Interestingly, replacement of the CCR2A C-terminus with the 
homologous region in CCR1 created a chimeric receptor capable of coupling to G15, as if the C-
terminus of CCR2 was preventing the interaction. 
The C-terminus of the receptor is palmitoylated and phosphorylated. There is the possibility that 
subcellular distribution might play an important role in defining coupling specificity and thus 
contribute specificity. 
In summary, but a few exceptions, the literature describes for G15 a peculiar flexibility that 
allows the recognition of a structural domain common to most GPCRs that in each case only 
becomes available in the active conformation. 
 
 
G15 in cancer 
 
The selective expression of Gα15 in hematopoietic cells and in activated T lymphocytes suggests 
that its presence could be associated to highly proliferating states. Several signal transducers 
involved in cancer development are among G15 effectors. In human lymphoblastoma Reh, 
endogenously expressed G15 stimulated by the α1 adrenergic receptor activated a signalling 
cascade leading to the activation of NF-κB. The effect was mediated by a combination of Gα15 
and Gβ1γ2 signalling aimed to IKK (Liu and Wong, 2004b). Gα15 activated the classical 
PLCβ/PKC/CaMKII pathway, likely directed toward the α and ε PKC isoforms. In parallel, the 
βγ branch of G15 signalling is directed toward c-Src (Liu and Wong, 2004b; Chan et al., 2002), a 
proto-oncogene prototype of an entire family of tyrosine kinase involved in malignant 
progression of tumors. 
As described above, upon agonist stimulation, multiple signals diverge from a GPCR (as when α 
and βγ subunits separate) often converging downstream at specific integration knots (Chan et al., 
2000; Lowes et al., 2002). In the case of G15 generated signals one potential locus for 
integration is the small GTPase Ras (Ito et al., 1995). The connection to Ras is provided for 
Gα15 by an adaptor protein named tetratricopeptide repeat 1 (Marty et al., 2003b) and for the 
Gβγ through Src, as long been shown in HEK 293 cells (Ito et al., 1995). Ras is known to initiate 
the Raf-1/MEK/ERK signalling cascade with a plethora of functional consequences including 
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IKK activation through direct interaction (Zhao and Lee, 1999) and through STAT3 (Lo et al., 
2003). 
A similar activation of MAPK signalling through G15, Src and Ras was also suggested in 
response to melatonin (Chan et al., 2002). All MAPK isoforms (ERK, JNK, p38) were shown to 
be activated by the constitutively active mutant form of G15 (Higashita et al., 1997; Chan et al., 
2002; Heasley et al., 1996) and, in addition to activate NF-kB (Yang et al., 2001), G15 was 
shown to produce STAT1-dependent c-Fos transcriptional activation (Lo and Wong, 2006). 
 
G15 and other Gq family members have previously been functionally analyzed for their potential 
role in cells transformation by utilizing vascular smooth muscle cells (Peavy et al., 2005) and 
Swiss-3T3 (Qian et al., 1994). The issue has been approached bypassing the GPCR and using a 
mutant form (Gα Q212L) of the G protein that becomes constitutively active because incapable 
of efficient GTP hydrolysis. Exogenous expression of the constitutively active form of Gα15 
leads to inhibition of cell growth in Swiss 3T3 fibroblasts (Qian et al., 1994)and to cell 
differentiation in PC12 cells (Heasley et al., 1996). However, these experiments should be 
interpreted with caution. The signal departing from a constitutively active Gα subunit is very 
different from the signal produced by a receptor activating the heterotrimer, the most compelling 
reason is that the latter does not release βγ subunit and thus does not activates βγ downstream 
effectors. Furthermore, coordinated signalling generated by the receptor toward other signalling 
cascades (see above) is likely missing. In addition, cells growing in culture could activate 
compensating mechanisms to counteract the expression of a constitutive active mutant. Finally, a 
strong and uncorrelated signal could activate cell death, as observed for Gq and G14 (Qian et al., 
1994; Peavy et al., 2005). Constitutively active Gq/11 produced PLCβ signals capable of 
inducing cell transformation at low levels of infection becoming toxic at higher levels (Kalinec et 
al., 1992). Therefore, the impact that G15 activation may play on neoplastic transformation 
remains to be determined when the effect is physiologically produced by a GPCR. 
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Materials and Methods 
Phosphoinositol accumulation 
 
Accumulation ofinositol phosphatewas measured by a modification of the method by Hung et al. 
(Zhu et al., 1994). COS-7 cells were grown in 12-wells tissue culture plates and 36 h after 
transfection, each well was supplemented with 2 µCi/ml of myo-[3H]inositol. Following 
overnight labeling, cells were rinsed three times at room temperature with 1 ml of washing buffer 
[Dulbecco’s phosphate buffered saline (D-PBS), supplemented with 5.5 mM glucose, 0.5 mM 
CaCl2, and 0.5 mM MgCl2]. Cells were then incubated at 37oC for 30 min in 0.5 ml D-PBS 
supplemented with 5 mM LiCl to inhibit inositol monophosphatase. The incubation was 
continued for 1 h at 37oC. Agonists were added 10 min after LiCl. At the end of the incubation, 
the supernatant was removed and 0.75 ml ice-cold 20 mM formic acid was added to each well to 
extract the producedinositol phosphate.inositol phosphate were separated from myo-[3H]inositol 
by a simplified ion exchange chromatographic procedure (Zhu et al., 1994). Briefly, after 1 hour 
on ice, the 20 mM formic acid extracts were applied to Dowex AG 1-X8, 100-200 mesh, formate 
form columns (0.6 cm diameter, 1.0 ml bed volume; BioRad, Hercules, CA) that had been 
sequentially pre-rinsed with 2 M ammonium formate/0.1 M formic acid, water, and 20 mM 
ammonium hydroxide adjusted to pH 9.0 with formic acid. Immediately after sample loading, 3 
ml of 40 mM ammonium hydroxide, pH 9.0, were added to each column and the eluates 
collected into vials containing 10 ml of scintillation fluid (ULTIMA-FLO AF; Packard 
Instruments Inc., Palo Alto, CA). These first eluates were previously shown to recover the vast 
majority (98%) of myo-[3H] inositol present in the samples (Zhu et al., 1994). The columns were 
then washed three times with 4 ml of 40 mM ammonium formate andinositol phosphate were 
eluted with 5 ml of 2 M ammonium formate/0.1 M formic acid into scintillation vials containing 
15 ml of scintillation fluid. To normalize the accumulation ofinositol phosphate over total 
[3H]inositol incorporated, the counts per minute of [3H]IP (last eluate) were divided by the sum 
of c.p.m. of myo-[3H]inositol (first eluate) plus c.p.m. of [3H]IP and expressed as percentages. 
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Western immunoblotting 
 
COS-7 cells were transfected as described in the previous paragraph. After removal of culture 
medium cells were lysed in Nonidet P-40 (NP40) buffer (150 mM NaCl, 10 mM Tris, pH 7.4, 
1% v/v NP40) containing protease inhibitor cocktail (Sigma Aldrich, Saint Louis, MO) and spun 
in a microcentrifuge at 11,000 x g. Alternatively 3-5 slices of frozen tumoral or healthy tissues 
were solubilized in the same buffer and treated according to the same procedure. 
Protein contents of supernatants were measured by the BCA assay (Pierce, Rockford, IL) and 
equal amounts of proteins were resolved by SDS-PAGE (10% acrylamide) and transferred to a 
Hybond-P membrane (GE Healthcare-Amersham, Piscataway, NJ). Membranes were blocked by 
incubation with 5% (w/v) nonfat dry milk and hybridized with primary antibodies. 
Anti-EE monoclonal antibody was obtained from Covance, Princeton, NJ. Anti-HA rabbit 
polyclonal antibody was from Abcam. Anti-HA  mouse monoclonal antibody was produced from 
12CA5 hybridoma. The anti-Ga16 Ab was obtained from Torrey Pines Biolabs (San Diego, CA). 
To detect the phosphorylated state of Ser744 and Ser748 located in the activation loop of PKD 
two different antibodies were used. One antibody (anti-pS744/pS748), obtained from Cell 
Signalling Technology (Beverly, MA), was raised against a peptide phosphorylated on serines 
equivalent to Ser744 and Ser748 of PKD but predominantly detects the phosphorylated state of 
Ser744 (Jacamo et al., 2008). Consequently, we refer to this antibody as anti-pS744. A second 
antibody, obtained from Abcam (ab17945), detects the phosphorylated state of Ser748. A third 
antibody was used to detect PKD (C20, Abcam). 
Secondary anti-mouse or anti-rabbit antibodies were horseradish peroxidase-conjugated (Pierce, 
Rockford, IL). Antigen-antibody complexes were detected using SuperSignal West Dura 
chemiluminescent substrates (Pierce, Rockford, IL) according to the manufacturer’s instructions, 
and visualized with Kodak Image Station 440 or X-ray film. 
 
cAMP accumulation 
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48 hours after transfection cells were washed twice with Ca2+/Mg2+-free PBS, incubated 15 min 
at 37°C in PBS supplemented with 4 mM EDTA, and scraped. After centrifugation cell pellets 
were resuspended at a density of 106 cells/90 µl in D-PBS supplemented with 5.5 mM 3-
isobutyl-1-methylxanthine. Samples were equilibrated for 15 min at 37°C and treated for 1 h 
with agonists or assay buffer (basal) at 37°C. cAMP accumulation was stopped by placing the 
tubes in liquid nitrogen and subsequent boiling for 5 min. Samples were then spun for 8 min at 
12,000 rpm in a microcentrifuge and supernatants were immediately used for the assay. cAMP 
content was quantified by means of a competitive binding cAMP assay kit (GE Healthcare-
Amersham) following manufacturer's instructions. 
 
Determination of cytosolic free Ca2+ levels 
 
Determination of cytosolic free Ca2+ concentrations ([Ca2+]i) was performed as previously 
described  (Capra et al., 2005). Briefly, HEK-293T cells were seeded on sterile coverslips coated 
with poly-D-lysine. After an incubation for 30 minutes at 30°C in the dark with 2 µM Fura 
2/AM, the dye was removed and the cells were further incubated for 30 min at 30°C to complete 
the Fura 2/AM hydrolysis. After loading, cells were washed twice with PBS and transferred to 
the spectrofluorimeter, where fluorescence was monitored at 37°C (505 nm emission, 340 and 
380 nm excitation). To extrapolate Ca2+ concentration from the fluorescence recording, the 
system was calibrated as follows: Fmax was obtained by adding 2 µM ionomycin and 100 µM 
digitonin, and Fmin was obtained by adding 5 mM EGTA and 60 mM Tris base. 
 
Co-immunoprecipitation 
 
COS-7 cells were grown and transfected in 100 mm tissue culture dishes using 4  µg of plasmid 
DNA encoding for HA tagged V2R-R137H, EE-tagged Gα subunits and β-arrestin 1. 48 h post-
transfection, cells were lysed in 1 ml of 100 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 
supplemented with protease inhibitor cocktail (Sigma Aldrich). After 1 h at 4oC, the particulate 
was removed from the samples by centrifugation at 21,000 x g. Immunoprecipitation was 
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performed for 16 h at 4oC using anti-HA monoclonal Ab previously crosslinked to CNBr-
activated Sepharose 4B beads (GE Healthcare-Amersham). Immune complexes were washed 
three times with 100 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.2% (v/v) NP-40 and eluted in 
Laemmli sample buffer. Samples were separated by SDS-PAGE (12% acrylamide) and analyzed 
by immunoblotting as described. 
 
Receptor internalization 
 
HA epitope tagged receptors in 12-well plates were incubated with or without agonist for 30 min 
in serum-free medium at 37°C. Cell surface receptors were labeled with 12CA5 mAb, and Alexa 
488-conjugated goat antibody against mouse IgG as a secondary antibody. Receptor 
internalization was quantified as loss of cell surface receptors as measured by fluorescence-
assisted cell sorting. 
 
Quantitative PCR analysis of mRNA 
 
Total mRNA was isolated from: tumoral cell lines, frozen tumor slices, healthy tissue or samples 
derived from xenografts. mRNA was extracted in Trizol, precipitated (isopropanol followed by 
70% ethanol) and random priming retrotranscribed by RT-PCR. The messenger expression level 
was next quantified by TaqMan PCR. Real-time analysis was performed on an ABI Prism 7000 
SDS (Applied Biosystems, Foster City, CA,USA) using the TaqMan PCR Master Mix (Applied 
Biosystems). The TaqMan assays were chosen from the list of the Assays-on-Demand (Applied 
Biosystems). The PCR reactions contained primers and probe diluted 1:20 and 5 ng c-DNA (total 
RNA equivalent) in 25 µL total volume, and samples were analyzed in triplicate. Thermal 
cycling included an initial incubation at 50°C for 10 minutes followed by 95°C for 10 minutes 
then 50 cycles of 15 seconds at 95°C for denaturation and 1 minute at 60°C for extension. 
Fluorescence emission of 6-carboxyfluorescein (FAM) was automatically measured during PCR 
run. A cycle threshold value of 45 was considered the end of the PCR run. The expression of 
each mRNA was calculated by relative quantification using the average of GAPD 
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(glyceraldehyde-3-phosphate dehydrogenase) (Hs99999905_m1) transcript level as reference. 
Data were analyzed as indicated in User Bulletin no. 2 (Applied Biosystems). 
 
Statistical Analysis 
 
Data were evaluated using GraphPad Prism version 11. Statistical comparison of multiple groups 
was performed using one-way ANOVA followed by Bonferroni's Multiple Comparison Test. 
Data are expressed as means ± S.E.M unless otherwise indicated. 
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Results 
 
 G15 expression in human tissues 
 
Circulating cells 
 
Human blood cells precursors were analyzed for the presence of Gα15. Hematopoietic 
derivatives were extracted from cord blood utilizing anti-CD34 immunomagnetic beads. Samples 
were lysated and examined by Western blot (Figure 8a). As expected (Lippert et al., 1997), a 
band corresponding to Gα15 appeared at 43 kDa. The presence of the protein in CD34positive 
Figure 8 - Expression of Gα15 by Western blot in cells derived from various human 
tissues. The 43 kDa band corresponding to Gα15 is indicated by the arrow. a) CD34 
positive cells were compared to an irrelevant cell line. b) peripheral blood mononucleated 
cells (containing CD34, CD8, CD4 positive cells, NK and dendritic cells) were stimulated 
with PHA for 2 to 7 days as indicated. c) epithelial cells derived from thymus. d) 
mesenchymal stem cells and e) various human tissues. A431 and PT45 represent positive 
controls (see below) while HEK (hamster embryonic kidney cells) represent negative 
control. 
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cells was associated to the correspondent mRNA (Figure 9) as assessed by TaqMan PCR. By 
contrast, Ficoll purified peripheral mononucleate cells obtained from the blood of a healthy 
donor did not display the 43 kDa band (Figure 8b). As reported for mature T cells by Lippert et 
al. (Lippert et al., 1997), elevated expression levels were obtained after 5 or more days of 
stimulation with phytohaemagglutinin (PHA). 
These experiments confirmed that Gα15 is present in immature lymphocytes, it becomes silenced 
upon maturation and quiescence but its expression can be restored when lymphocytes are 
activated and resume proliferation. 
 
 
 Solid tissues 
 
The analysis performed in circulating cells was extended to other tissues, including lymphoid 
organs. While virtually no mRNA signal could be detected in spleen, in thymus Gα15 expression 
was significantly higher 
(Figure 9). A strong 
positive signal was also 
observed in primary cell 
cultures from thymic 
medullary epithelial cells 
(TEC) (Figure 9). Also in 
this case, high mRNA 
levels were associated to a 
detectable amount of 
protein (Figure 8c). The 
robust presence of Gα15 in 
TEC suggests that the 
signal that we and others 
(Wilkie et al., 1991) 
observed in samples derived from whole thymus could be related to the endothelial component 
Figure 9 - Gα15 mRNA distribution in the human 
organism. The distribution of Gα15 mRNA was assessed by 
real time PCR in different tissues and cell preparations (as 
indicated). Data are expressed as relative expression (see 
material and methods) means ± SE. 
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rather than to the presence of immature lymphocytes in the lymphoid organ. In most human 
tissues a weak (but significantly higher than background level) signal was present, particularly in 
the skin (as previously reported (Rock et al., 1997a)) and in the heart. Contrary to CD34positive 
and TEC primary cells, specimens collected from various tissues were derived from a 
heterogeneous population. The contribution of few positive cells could therefore be masked by 
the background. Under these circumstances, substantially no protein was detected by Western 
blot. At this stage, it is not clear if the absence of a signal in the immunoblot is due to a lack of 
sensitivity of the antibody or rather to mRNA levels insufficient for a significant translation. 
 
Because Gα15 is expressed by immature stages of hematopoiesis, the question arose as to, in 
solid tissues, Gα15 could be analogously associated to remnants stem-like cells (i.e. 
mesenchymal stem cells). To address this issue, primary cultures of adult stem cells were derived 
from human thymus and from bone marrow. After confirming the presence of staminal markers 
(negative for CD31, CD45, CD73, CD80, CD86, HLADR2, VCAM, CD80; positive for CD29, 
CD44, CD105, MHCI), by flow cytometry, Gα15 mRNA was measured by PCR (Figure 9) and 
by Western blot (Figure 8d), however, no significant signal could be revealed. 
 
This argues against G15 mediating stem cell specific signalling, rather suggesting that Gα15 
could be present in cells with high proliferation potential, such as TEC, keratinocytes, 
CD34positive and activated T lymphocytes. Overall these results suggest that G15 may play a 
broader role than it was previously anticipated. Among Gq family members, G15 remains the 
one with the most restricted expression profile being virtually absent in most tissues. 
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 G15 signalling peculiarities 
 
G15 promiscuity 
 
To verify that G15 couples multiple GPCRs to PLCβ, we co-expressed its α subunit in COS-7 
cells with different GPCRs, namely the β2AR, DOR, V2R, fPR, CXCR4. 
Figure 10 –G15 signalling promiscuity in COS-7 cells. COS-7 cells were transfected with 
plasmids containing cDNAs as indicated and prelabeled with myo[3H]inositol overnight. 
Accumulation of [3H]inositol phosphates was measured in presence of 5 mM LiCl as 
described. The inositol phosphate isolated was normalized for the total amount of 
myo[3H]inositol incorporated (see materials and methods). Values are expressed as fold 
increase over the basal PLC activity level of cells transfected with an irrelevant plasmid 
(average±S.E.M, n=3 independent experiments performed in triplicate, ** P<0.005). a) Cells 
co-expressing Gα15 and β2AR stimulated by 10 µM Iso b) Cells co-expressing Gα15 and 
DOR stimulated by 10 µM DPDPE. c) Cells co-expressing Gα15 and V2R stimulated by 100 
nM AVP. d) Cells co-expressing Gα15 and FPR stimulated by 100 nM fMLP. e) Cells co-
expressing Gα15 and CXCR4 stimulated by 100 nM stromal derived factor 1 (SDF-1). 
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The β2AR is normally coupled to Gs and Gi, therefore it does not efficiently couple to PLC. In 
fact, as shown in Figure 10a, addition of 10µM Isoproterenol (Iso) to cultured COS-7 cells did 
not induce any significant increase in inositol phosphate production. The expression of Gα15 
with β2AR produced only a slight increase in inositol phosphate concentration, unless Iso was 
added inducing a dramatic increase above the background. Thus, Gα15 transfection made PLCβ 
responsive to Iso in COS-7 cells. 
A similar result was obtained with the DOR that is primarily coupled to Gi (Lee et al., 1998). 
Like in the case of the β2AR, inositol phosphate production could be stimulated by an opioid 
agonist (10µM [D-Pen2,5]-enkephalin (DPDPE)) provided that COS-7 cells were previously co-
transfected with Gα15 (Figure 10b). 
 
The V2R is naturally coupled to Gs (Rosenthal et al., 1993) and to Gq/11 (O'Connor and 
Cowley, Jr., 2007; Zhu et al., 1994). Accordingly, there was a significant increase in PLC 
activity in response to AVP. The expression of Gα15 enhanced V2R mediated PLC signalling 
(Figure 10c). 
G15 can also collect the signal of receptors displaying high basal activity. In fig. 9d it can in fact 
be noticed how, in the presence of Gα15, the chemotactic Gi coupled formyl peptide receptors 
(FPR) significantly promoted PLC activity already in the absence of the ligand. The signal is 
further increased upon addition of formyl Met-Leu-Phe, one of its natural agonists, consistent 
with the idea that only a minor fraction of FPR spontaneously acquires an active conformation 
(see introduction and Figure 4). 
Not all GPCRs activate G15 signalling. Among the few exceptions, are present chemokines 
receptors like CCR2 (see introduction), CCR5 and CXCR4 (Tian et al., 2008). PLCβ activity 
upon coexpression in COS-7 cells confirmed Gα15 refractoriness to CXCR4 activation. 
It can also be noticed how, in most cases, inositol phosphate accumulation was slightly increased 
by the presence of G15, even in the absence of GPCR co-expression. That could be possibly due 
to exogenous G15 spontaneous activity or to G15 collecting signals generated by active 
endogenous GPCRs. However, the low basal signal was present also without any cotransfected 
GPCR (data not shown) confirming that the β2AR, DOR and V2R do not display significant 
spontaneous activity. 
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β2AR signalling to G15 is poorly affected by β-arrestin desensitization 
 
We next determined whether G15 sensitivity to GPCR desensitization was similar to other G-
proteins. β-arrestin opposes prolonged GPCR activity (as described at pag. 11 in “GPCR 
regulation over time”) by preventing the stimulatory interaction of the receptor with the G 
protein. We utilized COS-7 cells, which express low levels of endogenous β-arrestins (Paing et 
al., 2002), to overexpress β-arrestin 1 and directly assess the efficiency of arrestin-dependent 
desensitization. As expected, β-arrestin 1 significantly (P<0.01) attenuated β2AR coupling to Gs 
Figure 11 - β2AR signalling through G15 resists β-arrestin dependent desensitization.  
The β2AR was transfected in COS-7 cells with or without β-arrestin 1. a) Stimulation of 
cAMP accumulation was compared by setting to 100% the maximal stimulation (10 µM Iso) 
obtained in control transfected cells (with β Gal cDNA instead of β-arrestin 1 cDNA). 
Stimulated β2AR dependent accumulation of cAMP was significantly dampened in cells co-
expressing β-arrestin 1 (**P < 0.01). Data represent average ± S.E.M. of three independent 
experiments performed in duplicate. b) The cotransfection of β-arrestin 1 did not produce a 
statistically significant effect on the stimulated β2AR dependent accumulation of inositol 
phosphate. Data represent average ± S.E.M of four independent experiments performed in 
triplicates. In the right side panels, immunoblotting analysis of the expression levels of β2AR 
(anti-HA antibody), Gα15-EE (anti-EE antibody), β-arrestin 1 and endogenous caveolin 1. 
Results 
 
 
39 
 
reducing the cAMP accumulation induced by 1 h stimulation with 10 µM Iso (Figure 11a). In 
striking contrast, β2AR coupling to G15 was substantially insensitive to β-arrestin 1 
overexpression, leaving unaffected agonist promoted inositol phosphate accumulation (Figure 
11b). 
To confirm that what observed for Gα15 was not the result of some indirect effect of the 
increased β-arrestin levels unrelated to GPCR desensitization, we monitored intracellular Ca2+ 
mobilization utilizing a protocol of desensitization based on repeated agonist stimuli in HEK-
293T cells. In this case HEK-293T cells were chosen because they express higher endogenous 
levels of β-arrestins as compared to COS-7. In addition, as described by Schmidt et al., in these 
cells the β2AR can activate Gs signalling directed to Ca2+ mobilization via PLCε (Schmidt et al., 
2001). Upon transfection with β2AR and either Gα15 or Gαq, we quantified the extent of the 
transient increase in intracellular Ca2+ concentration ([Ca2+i]) following Iso stimulation 
(challenge, Error! Reference source not found.); after washing away the ligand, cells were 
stimulated again and this second [Ca2+i] increase was also quantified (re-challenge). 
β2AR signalling through G15 resists 
desensitization induced by repeated 
stimulation.  [Ca2+]i elevation was 
induced by 10 µM Iso in HEK-293T cells 
co-expressing β2AR and similar levels of 
either Gα15 or Gαq carrying the same EE 
tag (Western blot in the inset panel). 
The peaks of [Ca2+]i transient were 
measured after the first agonist challenge 
(set as 100%) and upon re-addition of 
agonist after 5 minutes washout (re-
challenge). The response to the first Iso 
stimulation in cells transfected with 
Gα15-EE was 90% ± 13% than in cells 
transfected with GαqEE. Data represent 
means of [Ca2+]i stimulation over basal ± 
S.E.M. of at least three independent 
experiments performed in triplicate (**P 
< 0.01). 
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The response to the second challenge of 10 µM 
Iso was significantly attenuated (~50%, p<0.05) 
as compared to the first stimulation in the 
presence of Gαq but not in the presence of Gα15. 
It is not clear which G protein subunits 
participated to produce the [Ca2+]i transient. 
Possibly it was a combined effect of the Gαs 
subunit (indirectly activating PLCε) and of the 
Gβγ subunits released from Gs and Gi (activating 
PLCγ) (Schmidt et al., 2001). In any case, by two 
different approaches, we demonstrated that 
agonist induced signalling of the β2AR to G15 
was resistant to GPCR desensitization. 
We hypothesized that Gα15 interacts with the 
receptor so effectively to compete out not only β-
arrestins, but possibly also other G proteins. If 
this is the case, G15 presence should reduce the ability of GPCRs to couple to other G proteins. 
Indeed, the effect of Iso on cAMP accumulation was significantly reduced when Gα15-EE was 
co-transfected (Figure 12d). 
 
 
G15 resists to β-arrestin-dependent regulation of the DOR and the V2R. 
 
The poor sensitivity to β-arrestin-dependent desensitization was not unique to the signalling 
triggered by the β2AR. Inositol phosphate production stimulated by DPDPE in COS-7 cells co-
transfected with Gα15 and DOR was also unaffected by β-arrestin 1 overexpression (Figure 13). 
Unlike the β2AR and the DOR, in the case of the V2R the efficiency of β-arrestin dependent 
desensitization could not be analyzed without keeping into account the coupling toward 
Figure 12 - G15 competes Gs 
signalling. Co-transfection of Gα15 
significantly reduced (**P < 0.01) cAMP 
accumulation stimulated by 10 µM Iso in 
cells expressing the β2AR. Data represent 
average ± S.E.M. of three independent 
experiments performed in duplicates. 
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endogenous Gq and G11 (Figure 10c). In the absence of Gα15, the overexpression of ubiquitous 
β-arrestin 1 and 2 isoforms reduced to 35 ± 9% and 36 ± 11% (respectively) the inositol 
phosphate production induced by 100 nM arginine AVP via endogenous Gq/11 (Katz et al., 
1992) (see inset table in Figure 14).  
When Gα15 was co-transfected, a β-arrestin dependent reduction was still observed, as shown in 
the representative experiment in Figure 14. However, a large fraction of the stimulation was left 
intact. This result appears consistent with β-arrestin-dependent desensitization being effective 
only on the Gq/11 component leaving the G15 component unaltered. 
As an approximation to separate the G15 component from the Gq component, the values 
obtained in the absence of G15 were subtracted from the value obtained in presence of Gα15 (net 
of the basals). This operation was repeated for the control samples and for the two β-arrestins 
samples. The estimated G15 contribution to V2R signalling was totally unaffected by either β-
arrestin 1 or β–arrestin 2 overexpression. (Figure 14, inset table). 
Figure 13 - G15-mediated signaling of DOR and 
V2R is not affected by β-arrestin overexpression. 
In COS-7 cells transiently transfected with DOR and 
Gα15, 10µM of DPDPE stimulated inositol 
phosphate accumulation to the same extent in the 
absence or in the presence of overexpressed β-
arrestin 1. Values are expressed as fold increase over 
the basal PLC activity level of cells transfected with 
an irrelevant plasmid. Data represent average ± 
S.E.M. of three independent experiments performed 
in triplicates. 
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Figure 14 - G15-mediated signaling of V2R is not affected by β-arrestins overexpression. 
COS-7 cells expressing V2R with or without Gα15 and β-arrestin 1 or 2 (Western blot in the 
inset panels illustrate the expression levels of proteins as indicated) were stimulated with 
100nM AVP. One representative experiment performed in triplicate is shown (means±S.D.). 
The experiment described was repeated 4 times and mediated. The resulting values are 
reported in the inset panel. Gq/11-dependent stimulation in the absence of β-arrestins (control) 
and Gα15 overexpression was set as 100% in each experiment. β-arrestin-resistant 
desensitization (defined as the residual IP accumulation following β-arrestin overexpression) 
was calculated for the G15 component by subtracting the Gq/11 contribution (means±S.E.M.). 
x 
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Phosphorylation stabilizes 
β-arrestin binding to the 
receptor (Gurevich and 
Gurevich, 2003). We 
sought to rule out the 
possibility that only the 
phosphorylated form of 
the V2R was signalling 
through G15 by using a 
phosphorylation-resistant 
mutant. We previously 
demonstrated that shortening the V2R carboxyl-terminal tail by insertion of a stop codon at 
position 345 (V2R-S345ter) eliminates all phosphorylation sites without affecting the affinity for 
AVP or the coupling to Gs (Innamorati et al., 1997). Inositol phosphate accumulation induced by 
AVP was similar in cells having Gα15 co-expressed with V2R-S345ter or with V2R WT (Figure 
15). This ruled out a preferential interaction between G15 and the phosphorylated state of the 
receptor, suggesting that the protein complex forms regardless of the presence of the carboxyl-
terminus and its multiple phosphorylation sites (Innamorati et al., 1997).  
 
 
G15 reveals the activity of desensitized GPCR 
 
A mutant form of the V2R (V2R-R137H) has been proposed to be constitutively desensitized 
even in the absence of ligand. The substitution to histidine of the central arginine of the DRY 
motif stabilizes in fact the receptor in a conformation that remains stably associated to β-arrestin 
(Barak et al., 2001). As a consequence, the V2R-R137H is incapable of activating Gs and 
adenylyl cyclase (Barak et al., 2001; Rosenthal et al., 1993). Accordingly, the V2R-R137H 
transfected in COS-7 cells did not promote inositol phosphate accumulation, neither in the 
Figure 15 - G15 couples to 
non phosphorylated V2R - 
IP accumulation stimulated 
by 100 nM AVP was not 
different in COS-7 cells 
transfected with V2R-WT 
or with phosphorylation-
negative V2R-S345ter 
mutant. Values are the 
means±S.E.M. of three 
independent experiments 
performed in triplicate. 
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presence of endogenous Gαq/11, nor of overexpressed Gq (Figure 16) nor of overexpressed 
epitope tagged Gαq-EE (Figure 17a). 
x 
We hypothesized that G15 would be able to displace β-arrestin and recognize the 
Figure 17 - G15 couples to the constitutively desensitized V2R-R137H mutant. EE tagged 
Gαq and Gα15 were individually co-expressed with HA tagged V2R-R137H in COS-7 cells. 
Receptor dependent inositol phosphate accumulation is observed in presence of Gα15-EE 
(**P < 0.01) but not Gαq-EE. Values are expressed as fold increase over the basal PLC 
activity level of cells transfected with Gq and an irrelevant plasmid instead of V2R-R137H. 
Data represent average ± S.E.M. of four independent experiments performed in triplicates. In 
the right side panels, immunoblotting analysis of the expression levels of HA-V2R-R137H 
(anti-HA antibody), Gαq-EE and Gα15-EE (anti-EE antibody). 
Figure 16 - G15 couples to the 
constitutively desensitized V2R-
R137H mutant. Gαq and Gα15 
were individually co-expressed 
with either the V2R-WT or the 
V2R-R137H in COS-7 cells 
utilizing equivalent amount of 
cDNAs. In the case of the V2R-
R137H, receptor dependent IP 
accumulation is observed in the 
presence of Gα15 but not Gαq. 
Values are the means±S.D. 
obtained in one of three 
independent experiments. 
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hyperphosphorylated mutant. The V2R-R137H was thus co-expressed with Gα15 and inositol 
phosphate accumulation was measured. Gα15-EE and Gαq-EE as were expressed to comparable 
levels. The presence of Gα15-EE restored V2R-R137H signalling toward PLC. The effect was 
not due to an increase in receptor expression, since comparable receptor levels were present 
regardless of the type of β-subunit present (Figure 17b). 
Similar results were obtained utilizing equivalent amounts of cDNAs of the untagged versions of 
Gαq and Gα15 (Figure 16). Supporting the hypothesis that the V2R-R137H represents a receptor 
fully locked in an active conformation, AVP did not further increase V2R-R137H activity 
(Figure 17 and Figure 16). 
 
 
Molecular mechanism allowing G15 to couple to desensitized GPCR 
 
G15 appears therefore capable of circumventing the stable steric hindrance created by the tight 
interaction between β-arrestin and V2R-R137H (Barak et al., 2001). 
To gain some insight at the molecular mechanism that allows G15 to resist the effects of 
desensitization, co-immunoprecipitation experiments were set up to analyze the possibility that 
G15 displays a stronger affinity for the V2R-R137H as compared to other G proteins. 
All α subunits were expressed to similar levels (as assessed by direct comparison in Western 
blot) (Figure 18a). When equal amounts of the constitutively active receptor were precipitated 
(Figure 18b), only Gα15-EE was found associated to the V2R-R137H (Figure 18c). β-arrestin 
overexpression did not prevent the interaction of the V2R-137H with Gα15 (Figure 18d). 
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x Figure 18 Gα15 stably interacts with constitutively desensitized V2R-R137H. - a) EE 
tagged Gαq, Gα15 and Gαs were individually co-expressed with the HA tagged V2R-
R137H in COS-7 cells as indicated. a) Gα proteins total expression levels were compared 
by Western blot in whole cell lysate. The V2R-R137H was immunoprecipitated utilizing 
a monoclonal antibody against the HA epitope and immunoblotted with b) polyclonal 
antiHA or c) antiEE antibodies. d) Gα15 was co-immunoprecipitated with the V2R-
R137H as described above. The same amount of Gα15 was recovered (lower panel) in 
the presence or in the absence of β-arrestin 1 overexpression (upper panel). 
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One of the consequences of the stable interaction with β-arrestin (Wilbanks et al., 2002; Barak et 
al., 2003) is that most of the V2R-R137H is sequestered intracellularly (Barak et al., 2001; 
Rosenthal et al., 1994). We hypothesized that, by interacting with the mutant receptor, G15 could 
revert the constitutive internalization of the V2R-R137H and rescue it to the cell surface. 
The amount of receptor on the plasma membrane was monitored under non permeabilizing 
conditions by flow cytometry. An HA epitope placed at the amino-terminus of the receptor was 
utilized for this purpose. Gα15 expression restored a significant fraction of V2R-R137H to the 
cell surface. We also determined if β-arrestin overexpression could reverse this effect. However, 
as shown in Figure 19, β-arrestin had no effect on the number of V2R-R137H molecules 
expressed on the cell surface. 
This effect could be explained hypothesizing that the high affinity interaction of Gα15 with the 
Figure 19 - G15 restores cell surface expression of V2R-R137H. G15 restores cell surface 
expression of V2R-R137H. Cell surface expression of V2R-R137H was measured by flow-
cytometry in COS-7 cells transiently transfected with the indicated combinations of 
constructs. Fluorescent labeling of the receptor was achieved by an antibody directed to the 
amino-terminal HA epitope in unpermeabilized cells. a-d) FACS profiles representative of 
four experiments, the black trace represents cells transfected and treated as indicated, the gray 
trace represents mock transfected cells e) Specific surface fluorescence was quantified as 
percent of the V2R WT transfected in parallel and plotted as means±S.E.M. 
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receptor hinders the interaction with β-arrestin and thus set at least part of the receptor free to 
move to the cell surface. Further experiments are required to prove this hypothesis. 
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Gα15 activates effectors that favor tumor growth 
 
PKCs are among the best characterized effectors of Gq family members. Among PKCs isoforms 
PKDs have a major role in cell motility, invasion and adhesion (Wang, 2006). PKD also 
regulates tumor cell invasion and modulates cell motility and adhesion by binding to and 
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phosphorylating E-cadherin in prostate cancer cells. The pro-proliferative effect of PKD has 
been demonstrated in many cellular systems, including pancreatic carcinoma cells (Wang, 2006). 
We sought to assess if PKD is activated by G15 signalling. Gα15 was transfected in COS cells, 
together with PKD1, and directly stimulated with aluminum fluoride (AlF3) (Error! Reference 
source not found.). PKD1 activation level was revealed by Western blot measuring the 
phosphorylation of serine 744 and 748 with a phosphoaminoacid specific antibody. PKC 
dependent phosphorylation of these residues induces the activation of the catalytic domain and is 
thus considered to be indicative of PKD activity state. Very little stimulation was observed in 
cells overexpressing only PKD1. The presence of G15 potently strengthened the signal 
demonstrating that PKD1 can be included among downstream effectors of G15 signalling. 
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x 
The activatory effect was even more evident when G15 was activated by co-transfected β2AR. 
As shown in Figure 10, the simultaneous presence of the receptor and G15 made COS cells 
sensitive to Iso by inducing PLC activity. On turn, the stimulation was transmitted downstream 
by G15, but not Gq, to activate PKD1(Figure 21). In all cases PKD1 activation was reduced by 
the specific PKC inhibitor GF109203X. 
Figure 20 PKD1 activation by G15. - COS-7 cells were transfected as indicated with PKD1 
and the α subunits of different G proteins (G15, Gq or G11). The G proteins were directly 
activated by treatment with AlF3 for 2.5 or 60 minutes. 100 nM PDBu for 2.5 minutes instead 
directly activates PKCs. PKD1 activation level was quantified with antiphosphospecific 
antibodies against S748 or S744. In addition, the total level of PKD1 expression was 
measured by utilizing an antibody against PKD1 (C20). Gα15 expression level was 
monitored with specific antibodies. Pretreatment (1 h) with the specific inhibitor GF109203X 
prevented most of the activation. 
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PKD1 is upregulated by the V2R-R137H in presence of Gα15 
 
We next asked if G15 would collect the signal produced by the constitutively desensitized V2R-
R137H keeping as active an indirect downstream effector like PKD1 (Figure 22). The V2R-
R137H was thus compared to the WT after co-expression with Gα15 and PKD1. Similarly to the 
inositol phosphates accumulation assay, Western blot analysis revealed that even in the absence 
of the agonist the V2R-R137H kept a sustained phosphorylation of PKD1 (no difference on PKD 
phosphorylation could be detected if G15 was absent, data not shown). Once again the addition 
of AVP did not affect the signalling efficiency of the R137H mutant, while the activity of the 
WT was totally conditional to the presence of the agonist. Similar results were obtained probing 
S744 or S748. No effect on the total expression level of PKD1 or Gα15 was observed depending 
on the type of V2R expressed or on the treatment with AVP. 
Figure 21 – PKD1 
activation by G15. -COS-7 
cells were transfected with 
β2AR and PKD1 in addition 
to Gq or G15 prior treatment 
with Iso as indicated. PKD1 
activation level was 
quantified with the anti S748 
antibody. Pretreatment (1 h) 
with the specific inhibitor 
GF109203X prevented 
PKD1 activation. Equal 
amounts of PKD1 were 
expressed as assessed 
utilizing an antibody against 
PKD1 (C20). 
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Figure 22 - V2R-R137H sustains G15 dependent 
PKD1 activation. COS-7 cells were transfected with 
Gα15 and PKD1in addition to the receptor, either in 
WT or the R137H form. PKD1 activation level was 
revealed with the anti phosphorS744 or anti 
phosphoS748 antibody. Similar amounts of PKD1 
and Gα15 were expressed, as assessed by an 
antibody against PKD1 (C20) and Gα`15 
respectively. 
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Discussion 
 
Heterotrimeric G proteins support cellular signalling in virtually all aspects of cell physiology. 
G15 is a member of the ubiquitous Gq/11 subfamily that, for the last decade, was described as 
specific of hematopoietic stem cells (Wilkie et al., 1991; Amatruda, III et al., 1991; Hubbard and 
Hepler, 2006). Despite such relatively limited pattern of expression, the significance of its 
presence in our organism remains puzzling and surrounded by many mysteries. 
 
 
 Two Gα15 isoforms 
 
A first conundrum is represented by the observation that two different molecular weight forms 
were repeatedly described in immunoblot analyzing native Gα15. A 43 kDa form is predominant 
in normal granulomonocytic cells, whereas erythroid progenitors and platelets mostly express a 
46 kDa form. Activated T lymphocytes express both species (Lippert et al., 1997). 
Northern blot analysis performed on two cell lines, reports two transcripts (of 2.2 and 2.4 kb), 
however only one protein specie is detected in the corresponding Western blot (Wilkie et al., 
1991). This suggests that the two mRNA forms cannot explain the two protein products. Among 
other possible explanations, covalent post-translational modifications could be responsible for 
differential migration. Gα15 is indeed phosphorylated by PKC and palmitoylated. However, 
PKC phosphorylation does not cause a band shift as reported by Gu et al (Gu et al., 2003). As 
well, the removal of both the palmitoylated cysteine residues present at Gα15 N-terminus did not 
significantly affect the migration of the band corresponding to the recombinant protein (Pedone 
and Hepler, 2007). 
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However, the downmodulation of Gα15 expression by five different specific shRNA sequences 
(Error! Reference source not found.) proves that both bands are Gα15 and not to another isoforms 
or another protein recognized by a non specific interaction with the polyclonal antibody. 
This result validates the need for further investigations aimed to unravel the molecular details 
that differentiate these two Gα15 species. Further studies should also be dedicated to assess what 
differentiates their physiological roles. 
 
 
Expanding Gα15 expression profile 
 
Gα15 distribution is reported as restricted to tissues that are rich in hematopoietic cells and in 
cell types of hematopoietic origin (Hubbard and Hepler, 2006; Wilkie et al., 1991), i.e. spleen, 
bone marrow, embryonic liver and thymus. Consistent with an expression profile limited to 
hematopoiesis, in adult the signal is lost in liver and thymus. Furthermore, cell lines at different 
maturation stages (or inducible models, like HL60 cells) maintain Gα15 expression only in the 
progenitor cells status (Amatruda, III et al., 1991; Grant et al., 1997) to progressively decline it 
with maturation. This pattern was confirmed by Gα15 presence in CD34positive cells 
(Pfeilstocker et al., 2000) (Figure 8), erythroid cell lines (Ghose et al., 1999), megakariocytes 
(den Dekker et al., 2001), B cells progenitors (Mapara et al., 1995). We analyzed other immature 
adult cells (mesenchimal stem cells) derived from thymus and bone marrow, however, only 
minimal mRNA levels were present and no protein signal was detected in Western blot. Our data 
therefore indicate that, despite Gα15 expression overlaps the expression of a stemness marker 
like CD34, it cannot be generalized to all stem cells. 
A more comprehensive analysis of healthy tissues was in good agreement with the literature. 
However, traces of Gα15 mRNA were present in most tissues analyzed. Possibly, such a small 
number of transcripts only allows traslation below the detectability levels of the available 
antibodies (calculated by Krumins et al. to be <1 ng in HeLa cells (Krumins and Gilman, 2006)). 
Gα15 distribution should therefore be analyzed utilizing a better reagent. Unfortunately, the 
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similarity with other Gq family members limits the number of epitopes that can be designed to 
raise a more sensitive antibody. 
As described by Rock et al. (Rock et al., 1997a), skin makes an exception to what initially 
reported. We found that the expression levels in this tissue were comparable to the more 
homogeneous samples derived from hematopoietic cells and from TEC. Gα15 mRNA was 
reported in cultured cells from neonatal foreskin (but not in fibroblasts, melanocytes or 
endothelial cells) (Rock et al., 1997b). In situ hybridization revealed a strong expression 
specifically in epidermis and in hair follicular epithelium but not in other skin appendageal 
structures. 
We also showed that TEC are the major responsible for the signal present in adult thymus. TEC 
and keratinocytes share a common ectodermal origin while hematopoietic, endothelial and 
smooth muscle cells (in one report G15 has also been reported in tracheal smooth muscle cells 
(Bruges et al., 2007)) derive from a specialized subset of the mesoderm represented by blast-like 
colonies (named blast colony forming cell, BL-CFC) (Mikkola and Orkin, 2006). G15 signalling 
is therefore exploited by cells derived from at least two different germ layers leaving out tissues 
derived from the endoderm and healthy organs (like pancreas, gut and prostate). In summary, as 
for G14, G15 expression profile remains much more limited as compared to Gq and G11. 
However, its expression should not be considered as totally specific of the hemopoietic system 
and therefore its function should be analyzed within other contexts. 
 
 
 G15 interaction with the V2R-R137H reveals alternative receptor conformations 
 
Evolution diversified the sequence of Gα15 gene (GNA15) from other Gαq family members 
conferring to this G protein peculiar functional properties, not least the poor sensitivity to 
desensitization that we describe. Cells exploit GPCR desensitization to finely tune receptor 
activity and match the cellular responsiveness to the intensity of the stimulation. We observed 
that the coupling of distinct GPCRs (i.e. β2AR, DOR, V2R) to the promiscuous G15 protein is 
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remarkably resistant to the desensitization produced either by repeated stimulation, or by 
emphasizing β-arrestin function with overexpression. 
The process of receptor desensitization is not strictly limited to agonist-occupied receptors, 
rather, homologous phosphorylation and the subsequent interaction with β-arrestin also occur 
when the receptor becomes active either spontaneously (Innamorati et al., 2006) or because 
specific mutations lock it in an active conformation (Barak et al., 2001). One example is the 
V2R-R137H: this mutant V2R is uncoupled by desensitization from both Gs and Gq. Similar to 
other mutations found in rhodopsin (Robinson et al., 1992), in the α1B adrenergic receptor and in 
the angiotensin II type 1A receptor (Wilbanks et al., 2002), the constitutive activity promoted by 
the mutation of a conserved arginine residue is associated to high receptor phosphorylation, 
constitutive binding to β-arrestin and extensive intracellular translocation (see Introduction at 
pag. 17). Confirming the anomaly initially observed with the WT receptors, we find that G15 
demonstrates a differential sensitivity to V2R-R137H desensitization as compared to other 
heterotrimeric G protein subtypes, such as its homolog Gq (Figure 16, Figure 17, Figure 18, 
Figure 22). 
Two different substitutions in the same position of the F motif (R→L and R→C) are described 
for forcing the receptor toward constitutive activity without a correspondent significant initiation 
of the desensitization process. Consistently, patients carrying R137L or R137C substitutions 
suffer opposite symptoms to patients carrying the R137H substitution as they report antidiuresis 
despite absent AVP levels. Another mutation affecting the preceding aspartic residue (D136A) 
was reported to induce constitutive receptor activity (Morin et al., 1998) but in this case the 
spontaneous activation leaves large margin for the agonist to further promote receptor activity. 
All these mutations likely loosen intramolecular ionic forces that normally stabilize the inactive 
conformation thus facilitating the spontaneous transition to intermediate states of activation (see 
pag.9). It is possible that each one of these states simulates a receptor conformation, that is 
physiologically relevant for the activation of specific and alternative functions. 
The R137H substitution appears to shift the equilibrium entirely toward such active 
conformation, since, saturating all V2R-R137H binding sites with the agonist did not further 
stimulate G15 activity (as measured either by inositol phosphate accumulation or by PKD 
activation). However, under exactly the same experimental conditions, the addition of AVP 
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induced the internalization of the receptor rescued to the plasma membrane by the presence of 
G15 (Figure 19). The conformation stabilized by the R137H mutation therefore does not 
completely mimic the conformation induced by ligand occupancy. Consistent with the most 
recent theories on the presence of intermediate GPCRs conformations (see pag.10), a combined 
expression of G15 with the R137H mutant appears to drive the receptor toward a desensitized 
state that, although fully active on downstream effectors like PLC and PKD, it is not yet suitable 
to be recruited by the internalization machinery before the transition is completed by the 
interaction with the agonist. In other words, to explain why the activation of the effectors and the 
interaction with the internalization machinery are distinctly modulated by the agonist, we suggest 
that the presence of G15 modulates the conformation of the V2R-R137H to a state that 
represents an intermediate toward the full transition provoked by a full agonist. 
A similar functional disjunction of two phenomena that for longtime were believed to be inherent 
to a single activation state, is often referred as “biased agonism” because usually such 
dissociation is driven by different ligands. However, in this case, it is the results of a modulation 
driven by the G protein. This is not surprising as highly reminiscent of the so called “GTP effect” 
on the affinity of the receptor described many years ago (Birnbaumer, 2007). 
We foresee that these receptor conformations might exist to fulfill distinct functional effects on 
specific signalling pathways. 
 
 Molecular mechanism supporting G15 coupling to desensitized GPCRs 
 
Adding to the functional evidences offered by G15 effect on inositol phosphate accumulation, 
Ca2+ mobilization and PKD1 function, the ability of G15 to prevail GPCR desensitization better 
than other G proteins was substantiated by two additional observations. First, Gα15 displays a 
stronger interaction with the immunoprecipitated “desensitized” receptor (as compared to Gαs or 
Gαq). Second, there is a functional competition of Gα15 with functions mediated by β-arrestin 
(i.e. retaining intracellularly internalized V2R). 
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G15 is the most divergent member of the Gq/11 subfamily and it is characterized by a peculiar 
poor selectivity that permits coupling to most GPCRs (Offermanns and Simon, 1995). G15 poor 
sensitivity to β-arrestin dependent desensitization adds a novel feature to its atypical signalling 
properties.  
Alternative interpretations are available to explain the molecular mechanism(s) supporting G15 
remarkable resistance to β-arrestin desensitization. G15 could recognize a receptor activation 
domain left unshielded by β-arrestin docking. However, the simplest hypothesis is that a tight 
interaction of Gα15 with the receptor displaces β-arrestin and other G proteins from a common 
binding site. In retina exposed to intense light, rhodopsin desensitization is underlain by an 
analogous direct competition between the homologs of the G protein (transducin) and arrestin 
(cone arrestin) with the latter displacing transducin from a common docking region on rhodopsin 
(Krupnick et al., 1997). 
The phosphorylated carboxyl-terminus was not required for V2R coupling to G15 (Figure 15), it 
can therefore be inferred that G15 does not selectively associate with the phosphorylated form of 
the receptor. This does not completely exclude that G15 might privilege the “desensitized 
receptor”. In fact, partial desensitization (Innamorati et al., 1997) and β-arrestin binding (Oakley 
et al., 1999) occur even when the carboxyl-terminus has been artificially removed. However, 
since β-arrestin overexpression did not reduce G15 signalling, but neither amplified it, a 
preferential coupling of G15 to the complex formed by the receptor and β-arrestin appears 
unlikely. Consistently with the hypothesis of a particularly tight interaction of Gα15 with the 
receptor, it was recently shown that the stimulatory effect on Gq mediated by the viral 
chemokine receptor homolog pUS28 is markedly sensitive to the inhibition of G15 (Minisini et 
al., 2003). 
Explaining in deeper details the molecular determinants that allow G15 to recognize desensitized 
receptors as active might not be straightforward. As a matter of fact, G15 coupling promiscuity 
under ‘non-desensitizing’ conditions is still largely unexplained (despite the many attempts made 
by utilizing chimeric GPCRs or chimeric G proteins). As reported in the introduction, the 
molecular determinants driving the interaction with G15 seem localized in the second 
intracellular loop of the GPCR but may differ for each receptor type (Xie et al., 1997; Hubbard 
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and Hepler, 2006). At least for the α1b-adrenergic receptor, only a dramatic deletion of the 
second intracellular loop effectively prevented the interaction (Wu et al., 1995). 
On the β-arrestin side, the solution of the crystal structure of the β-arrestin-receptor complex 
remains elusive, and few available examples of mutagenesis clearly point to a multi-site 
interaction (Gurevich and Gurevich, 2006). In conclusion, thus far, not enough information is 
available to make accurate predictions or design a clear strategy aimed to dissect which domains 
allow G15 to override the desensitization process. 
 
 
 Physiological significance of G15 resistance to GPCR desensitization 
 
G15 has been acquired relatively late during evolution, likely by gene duplication (Davignon et 
al., 2000b) and has evolved at an accelerated rate as compared to all other Gα subunits genes 
(similar to many genes involved in functions that are specifically related to hematopoiesis 
(Murphy, 1993)). Why have mammalians evolved such peculiar G protein? What is the 
relevance of its signalling for our organism? 
Our data might offer a new perspective to answer these questions. We suggest that future 
investigations aimed to define Gα15 physiological function should keep into consideration that 
its effects may become more evident under conditions of intense and prolonged stimulation.  
‘Sustained’ G15 signalling could become particularly relevant to support enduring (and possibly 
ligand-independent) stimuli generated by GPCRs under exceptional stimulatory conditions, such 
as inflammation, organogenesis or tissue repair. Under similar circumstances, Gα15 could 
represent a mean to override the regulation that normally limits GPCR signalling. G15 is 
expressed within a short time window during early hematopoiesis (Hubbard and Hepler, 2006) or 
upon lymphocytes activation and cheratinocytes proliferation (Lippert et al., 1997). Gα15 normal 
expression could therefore be related to the need for producing potent and durable signalling 
when rapid and intense responses are required, see for instance upon antigen-induced 
lymphocytes activation and expansion. 
Discussion 
 
 
65 
 
Given its promiscuous nature, G15 could amplify signals generated by many GPCRs present in 
hematopoietic cells and in lymphocytes (including the vasopressin (Yamaguchi et al., 2004), 
adrenergic (Muthu et al., 2007; Kohm and Sanders, 2001) and opioid receptors (Messmer et al., 
2006; Steidl et al., 2004; Sharp, 2006)). S1P4 is a good candidate GPCR for promoting G15 
activity; it is part of a family of receptors responding to lysophospholipids or lysosphingolipids 
and it is involved in cell signalling of many different cell types. EDG6 (endothelial 
differentiation, G-protein-coupled 6), the gene that encodes for S1P4, is under the control of the 
same promoter of GNA15 (the gene encoding for Gα15) (Contos et al., 2002). Consistently, 
according to microarrays data, both genes are simultaneously expressed in mouse fetal liver 
cells, a model of erythroid differentiation, to become simultaneously silenced during 
differentiation (Antonella Ronchi, personal communication). An interaction between these two 
proteins could explain why in presence of serum (which is known to contain S1P (Yatomi et al., 
1997)) Gα15 inhibition or downregulation affects erythroid cells growth and differentiation 
(Ghose et al., 1999). 
Other scenarios could be anticipated under pathological circumstances involving protracted 
GPCR stimulation. G15 enduring signalling could be exploited by the pertussis toxin-resistant 
constitutive signalling generated by US28. US28 is one of the fourteen GPCRs encoded by the 
200kb genome of the human cytomegalovirus (HCMV). During HMCV infection in vitro, US28 
promiscuously couples to members of the Gi/o, G12/13 families of G-proteins and to G15 
(Billstrom et al., 1998; Minisini et al., 2003). Similar to many GPCRs, US28 demonstrates 
significant activity in the absence of ligands as reported by authors showing that US28 induces 
the activity of PLC in an agonist independent manner (Sherrill and Miller, 2008). US28 has been 
suggested to function as a viral oncogene since it can induce tumor formation in fibroblasts 
injected in nude mice. Such oncogenic effect involves G protein signalling aimed to induce the 
expression of proangiogenic and cell cycle factors (Sherrill and Miller, 2008).The signalling 
generated by this viral receptor is reminiscent of what we observed with the V2R-R137H as it 
occurs despite the carboxyl-terminus of the receptor is constitutively phosphorylated and 
internalization traps most of the receptors in perinuclear endosomes (Vischer et al., 2006). 
G15 poorly regulated signalling could also become relevant to other pathological conditions 
implying GPCRs hyperstimulation, as for instance in cancer development (Dorsam and Gutkind, 
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2007). In particular, G15 could create a “signalling shortcut” in tumors that produce large 
amounts of stimulatory peptides to self-stimulate their growth in an autocrine or paracrine 
manner (Heasley, 2001). 
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Conclusions 
 
In conclusion, upon prolonged GPCR activation, and while other G proteins are ineffective, G15 
stabilizes a receptor state that remains active towards intracellular effectors. By showing that the 
promiscuous coupling to G15 makes the V2R, β2AR and DOR more resistant to β-arrestin-
dependent desensitization, we suggest a novel mechanism by which GPCRs can generate 
sustained signalling. Such persistent activation of G15 will supposedly propagate to downstream 
effectors that include PKD in addition to other signal transducers potentially relevant to 
physiological conditions associated to intense signalling activity (such as inflammation). 
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